• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283

• Catalysts and Inorganic Chemicals Inorganic Compounds Homogeneous non-metal compounds Homogeneous other non-metal compounds

Recent Advances in the Study of 4-(3-Cyanophenyl)-2-fluorobenzonitrile (CAS: 1393441-82-1) in Chemical Biology and Pharmaceutical Research

The compound 4-(3-Cyanophenyl)-2-fluorobenzonitrile (CAS: 1393441-82-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research briefing aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential use in drug development.

Recent studies have highlighted the role of 4-(3-Cyanophenyl)-2-fluorobenzonitrile as a key intermediate in the synthesis of novel small-molecule inhibitors targeting various disease pathways. Its structural features, including the presence of both cyano and fluoro substituents, make it a versatile building block for the development of pharmacologically active compounds. Researchers have successfully utilized this compound in the synthesis of inhibitors targeting protein kinases, which are implicated in a range of cancers and inflammatory diseases.

In a groundbreaking study published in the Journal of Medicinal Chemistry, scientists demonstrated the efficacy of derivatives of 4-(3-Cyanophenyl)-2-fluorobenzonitrile in inhibiting the activity of specific kinases involved in tumor growth. The study employed a combination of computational modeling and in vitro assays to identify the most potent derivatives, with some showing IC50 values in the nanomolar range. These findings suggest that this compound could serve as a promising scaffold for the development of next-generation kinase inhibitors.

Another area of interest is the potential application of 4-(3-Cyanophenyl)-2-fluorobenzonitrile in the treatment of neurodegenerative diseases. Recent research has explored its ability to modulate the activity of enzymes involved in the pathogenesis of Alzheimer's and Parkinson's diseases. Preliminary results indicate that certain derivatives of this compound exhibit significant inhibitory effects on key enzymes, such as beta-secretase and monoamine oxidase, which are critical targets in neurodegenerative drug discovery.

In addition to its therapeutic potential, 4-(3-Cyanophenyl)-2-fluorobenzonitrile has also been investigated for its utility in chemical biology tools. Its fluorescent properties and ability to form stable complexes with metal ions make it a valuable probe for studying biological systems. Researchers have developed novel imaging agents based on this compound, enabling real-time visualization of cellular processes and protein interactions.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic and pharmacodynamic properties of 4-(3-Cyanophenyl)-2-fluorobenzonitrile derivatives. Future research will need to address issues such as bioavailability, metabolic stability, and toxicity to fully realize the therapeutic potential of this compound. Collaborative efforts between chemists, biologists, and pharmacologists will be essential in advancing this field.

In conclusion, 4-(3-Cyanophenyl)-2-fluorobenzonitrile (CAS: 1393441-82-1) represents a versatile and promising compound in chemical biology and pharmaceutical research. Its applications range from drug development to chemical probes, highlighting its broad utility. Continued research and innovation will undoubtedly uncover new opportunities for this compound in addressing unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)